New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
07:09 EDTLLYEli Lilly acquires all development rights for calcitonin peptide antibody
Eli Lilly and Company announced that, based on positive Phase 2 data, it has acquired all development rights for a calcitonin gene-related peptide, or CGRP, antibody currently being studied as a potential treatment for the prevention of frequent, recurrent migraine headaches. CGRP is a sensory neuropeptide with vascular and pro-inflammatory effects, two processes that have been implicated in migraine headaches. This novel molecule was discovered by Lilly scientists and then licensed to Arteaus Therapeutics for development in the clinical proof-of-concept study. Financial terms of the deal were not disclosed.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
07:08 EDTLLYIncyte sees epacadostat entering Phase 3 during 1H16
Incyte (INCY) said its position in the field of JAK inhibition is demonstrated by the ongoing commercial success of Jakafi and by the recent submissions, by Eli Lilly and Company (LLY), seeking regulatory approval of baricitinib for the treatment of rheumatoid arthritis. Baricitinib was licensed to Lilly by Incyte, and met the primary endpoint in all four of its global Phase 3 studies. If approved, Lilly expects to launch baricitinib in early 2017. In addition, epacadostat, Incyte's first-in-class IDO1 inhibitor, is expected to enter Phase 3 during the first half of 2016 in first-line advanced or metastatic melanoma in combination with Merck & Co's pembrolizumab. Multiple Phase 2, tumor-specific, expansion cohorts of epacadostat in combination with anti-PD-1 and anti-PD-L1 checkpoint modulators are also underway.
February 8, 2016
06:28 EDTLLYPharma trade group rolls out ad campaign aimed at lawmakers, WSJ says
The pharmaceutical industry is launching a new ad campaign with the intention of improving its reputation with lawmakers in an effort to lobby against drug price restrictions, the Wall Street Journal reports. The industry's biggest trade group the Pharmaceutical Research and Manufacturers of America, or PhRMA, says it plans to spend several million dollars this year, and 10% more than it spent last year, on digital, radio, and print advertisements that highlight the sector's role in developing new drugs and advancing medical science, the report says. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
February 1, 2016
06:18 EDTLLYTransition Therapeutics announces results from Phase 2 clinical study of TT401
Subscribe for More Information
06:11 EDTLLYTransition Therapeutics reports results from Phase 2 clinical study of TT401
Subscribe for More Information
January 29, 2016
05:20 EDTLLYEli Lilly, Adocia initiate Phase 1b study of BioChaperone Lispro U100
Adocia and Eli Lilly announced the initiation of a Phase 1b clinical trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly. This formulation uses Adocia's proprietary technology, BioChaperone, which is designed to enable the acceleration of insulin absorption. The study, under the Adocia-Lilly partnership, aims to compare the pharmacokinetic and pharmacodynamic profiles of BioChaperone Lispro to that of Humalog in 15 healthy Japanese subjects placed under euglycemic clamp.
January 28, 2016
09:55 EDTLLYEli Lilly nears test of key support at $80 area
Subscribe for More Information
06:29 EDTLLYEli Lilly backs FY16 adjusted EPS view of $3.45-$3.55, consensus $3.54
Backs FY16 revenue guidance of $20.2B-$20.7B, consensus $20.83B.
06:27 EDTLLYEli Lilly reports Q4 EPS 78c, consensus 78c
Reports Q4 revenue $5.38B, consensus $5.32B.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use